Intervention not reported
Nausea/vomiting* grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher nausea/vomiting* grade 3 or 4 (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Nephrotoxicity (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Anaemia grade 3 or 4 (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to higher anaemia grade 3 or 4 (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Hair loss (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention may leads to lower hair loss (safety population) (low certainty).
1 finding from 1 review
Intervention not reported
Leukopaenia (safety population) · women with metastatic triple‐negative breast cancer (mTNBC)
The intervention probably leads to higher leukopaenia (safety population) (moderate certainty).
1 finding from 1 review
Overall survival · women with early breast cancer
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Disease‐free progression · women with early breast cancer
Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Quality of life · women with early breast cancer
1 finding from 1 review
Febrile neutropenia · women with early breast cancer
Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Neuropathy (including grade 3/4 sensory or motor neuropathy, or both) · women with early breast cancer
Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Cardiotoxicity (including grade 3/4 and congestive cardiac failure) · women with early breast cancer
Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Development of LE · prevention of lymphoedema development
Lymphaticovenular anastomosis may leads to lower development of LE compared with standard care (low certainty).
1 finding from 1 review
Reduction of LE (%) · treatment of arm lymphoedema
It is very uncertain whether vascularised lymph node transfer changes reduction of LE (%) compared with standard care (very low certainty).
1 finding from 1 review
Number of infections per year · treatment of arm lymphoedema
It is very uncertain whether vascularised lymph node transfer changes number of infections per year compared with standard care (very low certainty).
1 finding from 1 review
Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · treatment of arm lymphoedema
It is very uncertain whether vascularised lymph node transfer changes pain score (1‐10; where 1 = no pain; 10 = extreme pain) compared with standard care (very low certainty).
1 finding from 1 review
Heaviness score (1‐10; where 1 = no heaviness; 10 = extreme heaviness) · treatment of arm lymphoedema
It is very uncertain whether vascularised lymph node transfer changes heaviness score (1‐10; where 1 = no heaviness; 10 = extreme heaviness) compared with standard care (very low certainty).
1 finding from 1 review
BASFI (score from 0 to 10, 0=excellent, 10=poor function) · treatment of arm lymphoedema
It is very uncertain whether vascularised lymph node transfer changes function score (1‐10; where 1 = good function; 10 = poor function) compared with standard care (very low certainty).
1 finding from 1 review
Quality of life · women with diagnosed breast cancer
1 finding from 1 review
Overall survival · women with diagnosed breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · women with diagnosed breast cancer
1 finding from 1 review